<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361100</url>
  </required_header>
  <id_info>
    <org_study_id>ONCORAL</org_study_id>
    <secondary_id>ET 2010-015</secondary_id>
    <nct_id>NCT01361100</nct_id>
  </id_info>
  <brief_title>Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract</brief_title>
  <official_title>Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinident Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentric feasibility study aimed to evaluate the Oncoral® test. The study
      includes 2 steps. The first one aims to validate the algorithm defined at the time when the
      test was developed in patients with different tumour stages. Patients will be enrolled before
      any treatment. They will immediately undergo the test. No follow-up will be realized. In
      total, 100 patients will be included in this first step. The estimated period of inclusion is
      6 months.

      If the algorithm is validated, the second step of the study will start. The purpose is to
      determine the characteristics of the test. Enrollment will concern smokers and alcohol
      drinkers at high risk of developing an epidermoid carcinoma of the upper aerodigestive tract.
      Patient follow-up will vary with both the result of the test and the biopsy, up to a maximum
      of one year. In total, 385 patients will be enrolled in this step during an estimated period
      of 18 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First step: Confirm that the parameters used for the development of the test to qualify it as positive or negative lead to the same level of sensitivity (98%)</measure>
    <time_frame>1 year after the beginning of enrollment</time_frame>
    <description>The algorithm was first defined when the test was developed in patients on different tumour stages .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second step: Determine the characteristics of the Oncoral® test</measure>
    <time_frame>2 years after the beginning of the second step enrolment</time_frame>
    <description>Sensitivity, specificity, positive predictive value, negative predictive value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First step: Estimation of test sensitivity</measure>
    <time_frame>1 year after the beginning of enrolment</time_frame>
    <description>Sensitivity will be assessed by the calculation : true positives / (true positives + false negatives)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second step : Estimation of test feasibility</measure>
    <time_frame>2 years after the beginning of the second step enrolment</time_frame>
    <description>Feasibility will be assessed by :
the rate of patients who were not able to realise the test (difficulty to rinse the oral cavity)
the rate of tests that cannot be analysed (inadequate tests, problems of stability, difficulties with the extraction of volatile molecules, DNA or mRNA...) If the rate of unusable tests is greater than 10%, corrective actions will be necessary in order to use this test in the future. These actions will be considered according to the type of problems (adjustments of the test, transport...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second step: Estimation of the prevalence of epidermoid carcinoma of the upper aerodigestive tract in the target population</measure>
    <time_frame>3 years after the beginning of the second step enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">485</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Oncoral test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oncoral® test</intervention_name>
    <description>The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.</description>
    <arm_group_label>Oncoral test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        First step:

          -  Man or woman aged more than 40 years

          -  With frequent alcohol intoxication and/or smoking

          -  With histologically confirmed epidermoid carcinoma of the upper aerodigestive tract

          -  No treatment delivered for this disease

          -  Signed, written informed consent

          -  Mandatory affiliation with a health insurance system

        Second step:

          -  Man or woman aged more than 40 years

          -  With frequent alcohol intoxication and/or smoking

          -  With no sign of an epidermoid carcinoma of the upper aerodigestive tract

          -  Signed, written informed consent

          -  Mandatory affiliation with a health insurance system

        Exclusion Criteria:

        First step:

          -  Previous history of cancer except carcinoma in situ of the uterine cervix or skin
             basal cell carcinoma treated with curative intent

          -  Gingivorrhagia when the test is realised

          -  Hypersensitivity to aspirin or to benzoate

          -  Asthmatic, diabetic patients or patents with chronic bronchitis requiring oxygen
             therapy

          -  Patients taking antibiotics at enrolment or during the previous week

        Second step:

          -  Previous history of cancer except carcinoma in situ of the uterine cervix or skin
             basal cell carcinoma treated with curative intent

          -  Patient already treated for a cancer

          -  Gingivorrhagia when the test is realised

          -  Hypersensitivity to aspirin or to benzoate

          -  Asthmatic, diabetic patients or patients with chronic bronchitis requiring oxygen
             therapy

          -  Patients on antibiotics at enrolment or during the previous week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ZROUNBA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie DUSSART, MD</last_name>
    <phone>+33 478 78 27 52</phone>
    <email>sophie.dussart@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justine SEMAL</last_name>
    <phone>+33 478 78 29 22</phone>
    <email>justine.semal@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux - Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erwan DE MONES DEL PUJOL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alban PASQUIES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel BABIN, MD Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé BENATEAU, MD Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent PATRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin HITIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David BLANCHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdellali ZAKHAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marie-Yolande LOUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yann MALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis LEFEBVRE, MD Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marian DEGARDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie EL BEDOUI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LARTIGAU, MD Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard COCHE-DEQUEANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean TON VAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis SCHIAPPACASSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauthier LEFEBVRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis GRAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe ZROUNBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier GIRODET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lofti BEN SLAMA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angélique GIROD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles DOLIVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie CORTESE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramina MASTRONICOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Castellsagué X, Quintana MJ, Martínez MC, Nieto A, Sánchez MJ, Juan A, Monner A, Carrera M, Agudo A, Quer M, Muñoz N, Herrero R, Franceschi S, Bosch FX. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer. 2004 Feb 20;108(5):741-9.</citation>
    <PMID>14696101</PMID>
  </reference>
  <reference>
    <citation>Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan;44(1):10-22. Epub 2007 Sep 6. Review.</citation>
    <PMID>17825602</PMID>
  </reference>
  <reference>
    <citation>Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers--a new diagnostic tool for oral cancer. Clin Cancer Res. 2006 Jul 1;12(13):3979-84.</citation>
    <PMID>16818695</PMID>
  </reference>
  <reference>
    <citation>Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer. 1998 Oct 29;78(3):390-1.</citation>
    <PMID>9766578</PMID>
  </reference>
  <reference>
    <citation>Peng G, Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Tisch U, Haick H. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010 Aug 10;103(4):542-51. doi: 10.1038/sj.bjc.6605810. Epub 2010 Jul 20.</citation>
    <PMID>20648015</PMID>
  </reference>
  <reference>
    <citation>Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005 Jul 7;3:27.</citation>
    <PMID>15987522</PMID>
  </reference>
  <reference>
    <citation>Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH, Wong DT. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004 Dec 15;10(24):8442-50.</citation>
    <PMID>15623624</PMID>
  </reference>
  <reference>
    <citation>El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, Clayman GL, Lippman S, Goepfert H. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn. 2001 Nov;3(4):164-70.</citation>
    <PMID>11687600</PMID>
  </reference>
  <reference>
    <citation>Liao PH, Chang YC, Huang MF, Tai KW, Chou MY. Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol. 2000 May;36(3):272-6.</citation>
    <PMID>10793330</PMID>
  </reference>
  <reference>
    <citation>Anker P, Lyautey J, Lederrey C, Stroun M. Circulating nucleic acids in plasma or serum. Clin Chim Acta. 2001 Nov;313(1-2):143-6.</citation>
    <PMID>11694252</PMID>
  </reference>
  <reference>
    <citation>Li Y, Zhou X, St John MA, Wong DT. RNA profiling of cell-free saliva using microarray technology. J Dent Res. 2004 Mar;83(3):199-203.</citation>
    <PMID>14981119</PMID>
  </reference>
  <reference>
    <citation>Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003 Aug 15;98(4):737-44. Erratum in: Cancer. 2003 Nov 1;98(9):2000.</citation>
    <PMID>12910517</PMID>
  </reference>
  <reference>
    <citation>Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay WP. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999 Jun 5;353(9168):1930-3.</citation>
    <PMID>10371572</PMID>
  </reference>
  <reference>
    <citation>Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis--focus on volatile organic compounds. Clin Chim Acta. 2004 Sep;347(1-2):25-39. Review.</citation>
    <PMID>15313139</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>October 1, 2012</last_update_submitted>
  <last_update_submitted_qc>October 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Otolaryngology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

